Overcoming eDiscovery Challenges for Government Agencies

whitePaper | September 15, 2022

Entities around the globe are using collaboration solutions to evolve the way they do business. From schools to financial institutions to government agencies, organizations everywhere rely on solutions like the Zoom platform for collaboration and communication.

whitePaper | December 2, 2019

The Autumn 2018 Budget commits HM Government to review how it can use Artificial Intelligence (AI), automation and data in new ways to drive public sector productivity and wider economic benefits.

whitePaper | March 16, 2022

A long-term commitment to sustained federal research and development (R&D) funding in AI is critical to advance the United States’ leadership in global innovation. The federal government should increase non-defense investment in AI and basic research to strengthen research in critical fields of AI R&D, including healthcare, education, finance, and more, that underpin economic stability and robust growth. Such investment should reflect a multidisciplinary approach, focused on advancing basic and applied R&D, research on AI governance and norm-setting, and supporting research infrastructure with multi-agency collaboration.

whitePaper | November 9, 2019

The underlying driver of the ongoing US–China trade war is a race for global technological dominance. President Trump has raised a number of issues regarding trade with China – including the US’s trade deficit with China and the naming of China as a currency manipulator. But at the heart of the ongoing tariff escalation are China’s policies and practices regarding forced technology transfer, intellectual property theft and non-market distortions.

whitePaper | June 1, 2022

These are challenging times for the UK, but the economy is recovering well, with record job vacancies and unemployment back at pre-crisis levels. A diverse range of companies and entrepreneurs continue to identify the UK as a great place to start and grow a business. The UK continues to be Europe’s most attractive location for international investment in financial services and is well positioned for continued growth1. To help people cope with rises in the cost of living, we want to see businesses thrive across the whole of the UK, sustaining employment and the economic health of communities.

whitePaper | February 12, 2020

Both the U.S. Government and biopharmaceutical industry have been central engines for developing new medical treatments and cures, thereby lowering the effective price of better health for patients worldwide. The sector has done so by being both the world leader in these biopharmaceutical cures and treatments as well as the source of the returns that are required to fund new medical R&D investments.